Imagine being able to read a menu or a text message without fumbling for your reading glasses. That's the hope for people with presbyopia, the age-related condition that makes close-up vision blurry. A small, completed study tested three different eye drop formulas—BRIMOCHOL™, BRIMOCHOL™ F, and carbachol—to see if they could help. The study involved 18 people who either had their natural lens or an artificial lens implant. The main goal was to see how many people could gain a significant improvement in their near vision (reading letters up close) without losing any meaningful distance vision. The study was designed as a crossover trial, meaning each person tried the different drops in a random order, and neither the participants nor the doctors knew which drop was being used at any time. This type of design helps get a clearer picture of how the treatments compare. The abstract confirms the study is finished, but it does not share the specific findings on how safe the drops were or how well they worked compared to each other. The results were posted in early 2025.
Could new eye drops help you read without reading glasses?
Plain Language Summary
What this means for you:
A small study compared three eye drops for reading vision, but results are not detailed in the abstract. What this means for you:
A small study compared three eye drops for reading vision, but results are not detailed in the abstract. View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2
Condition(s): Presbyopia
Intervention(s): BRIMOCHOL™ (DRUG), BRIMOCHOL™ F (DRUG), Carbachol (DRUG)
Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia
Detailed: A 3-Dose, Multicenter, Randomized, Double-Masked, Crossover Phase 2 Safety and Efficacy Study of BRIMOCHOL™ Topical Ophthalmic Solution vs. BRIMOCHOL™ F Topical Ophthalmic Solution vs. Monotherapy with Carbachol Topical Ophthalmic Solution in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia
Primary Outcome(s): Proportion of Subjects With a >=15 Letter Gain Without a < 5 Letter Loss in Near Visual Acuity
Enrollment: 18 (ACTUAL)
Lead Sponsor: Visus Therapeutics
Start: 2021-03-24 | Primary Completion: 2021-10-19
Results posted: 2025-02-05